Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Documenti analoghi

• Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes
  di: Lasin Ozbek, et al.
  Pubblicazione: (2026)
• Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
  di: Rayanne Santos de Paulo, et al.
  Pubblicazione: (2026)
• GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
  di: Giorgia Rutigliani, et al.
  Pubblicazione: (2026)
• Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
  di: Roberta Scairati, et al.
  Pubblicazione: (2026)
• Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
  di: Binayak Sinha, et al.
  Pubblicazione: (2025)